Lucknow Speciality Pharma

Ado-trastuzumab Emtansine Injection 160 mg
Trastuzumab emtansine is used to treat certain types of breast cancer. This medication is used to treat tumors that produce more than the normal amount of a certain substance called HER2 protein. This medication is called a monoclonal antibody and microtubule inhibitor conjugate. To get access, please contact Patient Support Team @ +91 9760014849 / 9555306364 / 9794360370 / 9140551027, Time 9 am - 8 pm IST or send us a request on email (urgent@lucknowpharma.com) / WhatsApp for the same.
Get Access Price
WhatsApp

Ado-trastuzumab Emtansine Injection was approved for medical use in the United States in 2019. It is on the World Health Organization’s List of Essential Medicines.

Ado-trastuzumab Emtansine Injection Available Price In Lucknow Banaras Nepal

Ado-trastuzumab Emtansine Injection

  • Generic Brand Available – Kadcyla
  • API – Ado-trastuzumab Emtansine
  • Packaging – Glass Bottle
  • Strength – 160 mg

What is Ado-trastuzumab Emtansine Injection used for?

Ado-trastuzumab Emtansine Injection, Kadcyla (ado-trastuzumab emtansine) is a new class of chemotherapy drug called an antibody-drug conjugate used to treat breast cancer.

 

About Us

Lucknow Speciality Pharma is dedicated to delivering life-changing healthcare solutions. As a trusted wholesale supplier of specialized medicines, we cater to critical care areas such as oncology, nephrology, and rare diseases. Our patient-centric approach also includes personalized catering services, ensuring that patients receive the care, support, and nutrition they need to thrive. We also extend our services globally, welcoming international patients and buyers who seek our expertise and high-quality products.

Lucknow Speciality Pharma is a registered Pharmaceutical Firm in Lucknow, India. Registered under GST Act. Registration Number : 09AAOPG3102HIZY. It provide assistance and connectivity with drug pharmacies or distributors for access to genuine medicines at competitive prices. 

Get Access To Ado-trastuzumab Emtansine Injection 160 mg

Enter Buying Requirements Details

For precise quotations, kindly ensure your requirements include the product name, order quantity, intended usage, and any special requests you may have.

Branch Offices in India : Lucknow | Agra | Varanasi | Gorakhpur | Kanpur | Indore | Patna | Kolkata | Nepal

FAQs – Medicine Questions

Ado-trastuzumab Emtansine Injection 160 mg
Is ado-trastuzumab emtansine chemo?
Kadcyla (ado-trastuzumab emtansine) is a new class of chemotherapy drug called an antibody-drug conjugate used to treat breast cancer.
What is ado-trastuzumab emtansine used for?
Ado-trastuzumab emtansine injection is used to treat HER2-positive metastatic breast cancer (cancer that has spread) in patients who have previously received other medicines (eg, trastuzumab, taxane medicine) that did not work well or whose cancer has returned during or within 6 months of completing treatment.
Do you lose your hair with Kadcyla?
Kadcyla doesn’t cause hair loss in most people who take the drug. And hair loss wasn’t reported as a side effect in Kadcyla’s prescribing information. In a trial that compared Kadcyla with another cancer treatment, hair loss did occur. But it wasn’t a common side effect with either drug.
Where can I buy Ado-trastuzumab Emtansine Injection?

You can buy Ado-trastuzumab Emtansine Injection from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

The buyer should check the existing law in their home country before importing the product.

What is the procedure to buy Ado-trastuzumab Emtansine Injection?

Patients can simply fill the order form or can send mail at info@lucknowpharma.com. Patients can also send WhatsApp messages to +91-9555306364 We will reply ASAP with the details of the Ado-trastuzumab Emtansine price as well as procurement procedure.

Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.

What is the success rate of Kadcyla?
The study was designed to measure disease-free survival, which is how long the patient stayed alive and cancer-free. After 3 years, the rate of disease-free survival was 88% in the Kadcyla group compared with 77% in the Herceptin group.

NEWS / UPDATES

  1. Genentech Inc, [Revised on Sep 2020] [Accessed on 8th Apr 2021], https://www.gene.com/download/pdf/kadcyla_prescribing.pdf
  2. Roche Products Limited, Electronic Medicines Compendium (EMC), [Revised on Jul 2021] [Accessed on 4th Dec 2021], https://www.medicines.org.uk/emc/files/pil.5252.pdf
  3. Gunter von Minckwitz et al., Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer, N Engl J Med 2019; 380:617-628 [Accessed on 8th Apr 2021],  https://www.nejm.org/doi/full/10.1056/NEJMoa1814017
  4. Barok et al., Trastuzumab emtansine: mechanisms of action and drug resistance, Breast Cancer Research 2014, 16:209, [Accessed on 8th Apr 2021], https://www.researchgate.net/publication/262780064_Trastuzumab_emtansine_Mechanisms_of_action_and_drug_resistance